MBX peer analysis
MBX Biosciences (MBX) against its competitors: price, today's move, 1-year return and market value side by side.
MBX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALT Altimmune | $1.94 | -8.73% | -44.80% | $402.65M |
| ASND Ascendis Pharma | $256.06 | -1.46% | 29.87% | $16.90B |
| BMEA Biomea Fusion | $0.50 | -15.56% | -58.20% | $40.60M |
| KLRA Kailera Therapeutics | $14.25 | 4.01% | – | $1.73B |
| LPCN Lipocine | $1.72 | 9.55% | -40.23% | $16.94M |
| ORMP Oramed | $4.00 | 3.63% | 73.66% | $161.81M |
| RYTM Rhythm Pharmaceuticals | $114.00 | 0.05% | 13.40% | $7.82B |
| SKYE Skye Bioscience | $0.69 | -30.32% | -91.39% | $4.60M |
| VKTX Viking Therapeutics | $28.74 | -0.86% | -26.51% | $3.42B |
| XERS Xeris Biopharma | $15.81 | -0.28% | 53.50% | $2.77B |
| MBX MBX Biosciences | $56.45 | 4.42% | 127.72% | – |
- MBX's peers: ALT (Altimmune), ASND (Ascendis Pharma), BMEA (Biomea Fusion), KLRA (Kailera Therapeutics), LPCN (Lipocine), ORMP (Oramed), RYTM (Rhythm Pharmaceuticals), SKYE (Skye Bioscience).
Updated 2026-11-11 00:48 UTC